Related Experiment Video
Updated: Aug 5, 2026

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
Published on: February 9, 2024
Prolonged wild-type p53 protein accumulation and cisplatin resistance
E M Yazlovitskaya1, R D DeHaan, D L Persons
1Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, Kansas 66160, USA.
Cisplatin resistance in ovarian cancer cells is linked to prolonged stabilization of the p53 protein. This study reveals that resistant cells require higher cisplatin doses and longer exposure to activate the p53 pathway.
Area of Science:
- Molecular Biology
- Cancer Research
- Biochemistry
Background:
- Cisplatin is a key DNA-damaging chemotherapeutic agent.
- Tumor resistance to cisplatin limits its clinical efficacy.
- The p53 pathway is crucial for cellular response to DNA damage.
Purpose of the Study:
- To investigate the role of the p53 pathway in cisplatin resistance.
- To compare cisplatin-induced p53, p21WAF-1, and Mdm2 responses in sensitive and resistant ovarian cancer cells.
Main Methods:
- Utilized cisplatin-sensitive (A2780) and resistant (CP70) ovarian carcinoma cell lines.
- Assessed protein levels and half-life of p53, p21WAF-1, and Mdm2 following cisplatin treatment.
Main Results:
- Resistant CP70 cells required higher cisplatin doses and longer exposure for p53, p21WAF-1, and Mdm2 accumulation compared to A2780 cells.
- Cisplatin induced a significantly longer p53 protein half-life (31-fold increase) in CP70 cells versus A2780 cells (6-fold increase).
- No significant difference in p21WAF-1 half-life was observed between the cell lines.
Conclusions:
- Cisplatin resistance in these ovarian cancer models correlates with prolonged p53 protein stabilization and accumulation.
- Altered p53 protein dynamics may be a key mechanism underlying cisplatin resistance.
More Related Videos
Related Concept Videos
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
Abnormal Proliferation
Treatment Resistant Cancers
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
DNA Damage Can Stall the Cell Cycle

